Company Overview
Pharming Group N.V. operates as a biopharmaceutical entity dedicated to the development and commercialization of protein replacement therapies and precision medicines specifically for the treatment of rare diseases across the United States, Europe, and international markets. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to address unmet medical needs through advanced therapeutic modalities. In terms of scale, Pharming Group N.V. carries a market capitalization of $1.10B while reporting annual revenue of $376.13M, though employee count data is not currently disclosed in the available records. These financial dimensions indicate that the company holds a mid-sized capitalization profile within the biotechnology landscape, suggesting a significant operational footprint relative to early-stage peers but without the massive revenue base of established large-cap pharmaceutical firms, which often correlates with high growth potential in niche therapeutic areas like rare disease management.
Financial Health
The company generated revenue of $376.13M over the trailing twelve months, resulting in a net income of $2.85M and an EBITDA of $43.46M. The substantial disparity between the $376.13M in revenue and the $2.85M in net income highlights a cost structure where operational expenses and taxes consume the vast majority of top-line sales, leaving a profit margin of only 0.8%. Despite the modest net income, the entity generated free cash flow of $63.69M, which indicates a strong ability to convert earnings into cash, providing substantial financial flexibility for research and development activities or debt servicing. The gross margin stands at 87.9%, reflecting the high-margin nature of biotechnology product sales, while the operating margin of 5.8% suggests significant overhead costs relative to gross profits before accounting for the final tax impact. Regarding liquidity and leverage, the company holds $179.10M in cash against $115.78M in debt, supported by a debt-to-equity ratio of 41.78 and a current ratio of 2.59. The current ratio of 2.59 signifies robust short-term liquidity, meaning the company possesses more than double the current assets necessary to cover its current liabilities. Return on Equity is recorded at 1.0% and Return on Assets at 4.5%, metrics that reveal that while the company generates positive returns on its asset base, the equity base is large relative to net income, which dilutes the return percentage for shareholders.
Valuation Assessment
Pharming Group N.V. trades with a trailing P/E ratio of 396.00 and a forward P/E of 391.11. The minimal difference between the trailing and forward P/E ratios implies that the market expects earnings growth to closely mirror current levels rather than a dramatic acceleration or deceleration in the near future. The price-to-book ratio is 37.89, indicating that the stock is trading at a significant premium over its book value, a common characteristic for biotechnology companies where intangible assets like intellectual property drive value rather than physical assets. Alternative valuation metrics such as the price-to-sales ratio of 2.93 and an EV/EBITDA of 232.70 suggest that the market is willing to pay a high multiple for the company's revenue and earnings before interest, taxes, depreciation, and amortization, reflecting confidence in future commercialization potential. The 52-week price range spans from a low of $7.50 to a high of $21.34, and given the forward P/E of 391.11, the current valuation implies a price point well above the recent low, positioning the stock significantly within its historical volatility band. The beta value of 0.16 indicates that the stock exhibits very low price volatility relative to the broader market, moving much less than the overall index and offering a distinct risk profile for portfolios seeking lower correlation with general market swings.
Growth & Income
Pharming Group N.V. reported a revenue growth rate of 14.9% year-over-year alongside an earnings growth rate of 98.1% year-over-year. The fact that earnings are growing at a rate nearly seven times faster than revenue implies that the company is successfully scaling its operational efficiency or realizing significant margin expansion from new product launches or cost reductions. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which explains that the entity reinvests all generated earnings directly into growth initiatives, research, and development rather than distributing capital to shareholders. This strategy prioritizes expansion in the rare disease therapeutic space over immediate income generation for investors. Overall, the growth and income profile is characterized by aggressive top-line expansion and exceptional earnings acceleration, funded by a balance sheet that prioritizes reinvestment over dividend distribution.